PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE
Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 x 109/l at baseline coul...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PAGEPress Publications
2012-06-01
|
| Series: | Mediterranean Journal of Hematology and Infectious Diseases |
| Subjects: | |
| Online Access: | http://www.mjhid.org/index.php/mjhid/article/view/371 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850059154446614528 |
|---|---|
| author | Simone Baldini Luigi Rigacci Valentina Carrai Renato Alterini Rajmonda Fjerza Alberto Bosi |
| author_facet | Simone Baldini Luigi Rigacci Valentina Carrai Renato Alterini Rajmonda Fjerza Alberto Bosi |
| author_sort | Simone Baldini |
| collection | DOAJ |
| description | Patients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 x 109/l at baseline could distinguish subjects with such response from those with a delayed one during the early phase of treatment. Our work is a retrospective and single-institution analysis comparing the median platelet count, the median weekly dosage of romiplostim and the median number of weekly platelet counts < 50 x 109/l between patients with a baseline ≥ 20 x 109/l platelets (n=10, 2 splenectomized) and those with a lower one (n=8, 3 splenectomized) during the first month of treatment with romiplostim. The results show a higher median platelet count (79,5 vs 40,5 x 109/l, p=0,002) and a lower median dose of romiplostim (1 vs 2 mcg/kg/week, p=0,01) in subjects with a baseline ≥ 20 x 109/l platelets, who also had a trend of less weekly counts < 50 x 109/l platelets (1 vs 2, p=0,054). These data suggest that patients with ≥ 20 x 109/l platelets at baseline may achieve a prompt response with the standard dose of romiplostim, but further and larger data are needed in order to assess whether it can be considered in clinical practice. |
| format | Article |
| id | doaj-art-88ddecb0f2804869905f0000e776cb52 |
| institution | DOAJ |
| issn | 2035-3006 |
| language | English |
| publishDate | 2012-06-01 |
| publisher | PAGEPress Publications |
| record_format | Article |
| series | Mediterranean Journal of Hematology and Infectious Diseases |
| spelling | doaj-art-88ddecb0f2804869905f0000e776cb522025-08-20T02:50:57ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062012-06-0141e2012044e201204410.4084/mjhid.2012.044263PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCESimone Baldini0Luigi Rigacci1Valentina Carrai2Renato Alterini3Rajmonda Fjerza4Alberto Bosi5University of Florence, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyUniversity of Florence, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyUniversity of Florence, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyUniversity of Florence, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyUniversity of Florence, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyUniversity of Florence, Hematology Unit, Azienda Ospedaliero-Universitaria Careggi, Florence, ItalyPatients with chronic immune thrombocytopenia treated with romiplostim may benefit from a higher starting dose when a rapid increase in count is needed, but it could be avoided in those with a prompt response to the standard dosage. We hypothesized that a platelet count ≥ 20 x 109/l at baseline could distinguish subjects with such response from those with a delayed one during the early phase of treatment. Our work is a retrospective and single-institution analysis comparing the median platelet count, the median weekly dosage of romiplostim and the median number of weekly platelet counts < 50 x 109/l between patients with a baseline ≥ 20 x 109/l platelets (n=10, 2 splenectomized) and those with a lower one (n=8, 3 splenectomized) during the first month of treatment with romiplostim. The results show a higher median platelet count (79,5 vs 40,5 x 109/l, p=0,002) and a lower median dose of romiplostim (1 vs 2 mcg/kg/week, p=0,01) in subjects with a baseline ≥ 20 x 109/l platelets, who also had a trend of less weekly counts < 50 x 109/l platelets (1 vs 2, p=0,054). These data suggest that patients with ≥ 20 x 109/l platelets at baseline may achieve a prompt response with the standard dose of romiplostim, but further and larger data are needed in order to assess whether it can be considered in clinical practice.http://www.mjhid.org/index.php/mjhid/article/view/371ITPromiplostim: platelet count |
| spellingShingle | Simone Baldini Luigi Rigacci Valentina Carrai Renato Alterini Rajmonda Fjerza Alberto Bosi PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE Mediterranean Journal of Hematology and Infectious Diseases ITP romiplostim: platelet count |
| title | PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE |
| title_full | PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE |
| title_fullStr | PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE |
| title_full_unstemmed | PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE |
| title_short | PATIENTS WITH ≥ 20 X 109/L PLATELETS AT BASELINE MAY HAVE A PROMPT RESPONSE TO ROMIPLOSTIM DURING THE EARLY PHASE OF TREATMENT: AN ITALIAN SINGLE-INSTITUTION EXPERIENCE |
| title_sort | patients with ≥ 20 x 109 l platelets at baseline may have a prompt response to romiplostim during the early phase of treatment an italian single institution experience |
| topic | ITP romiplostim: platelet count |
| url | http://www.mjhid.org/index.php/mjhid/article/view/371 |
| work_keys_str_mv | AT simonebaldini patientswith20x109lplateletsatbaselinemayhaveapromptresponsetoromiplostimduringtheearlyphaseoftreatmentanitaliansingleinstitutionexperience AT luigirigacci patientswith20x109lplateletsatbaselinemayhaveapromptresponsetoromiplostimduringtheearlyphaseoftreatmentanitaliansingleinstitutionexperience AT valentinacarrai patientswith20x109lplateletsatbaselinemayhaveapromptresponsetoromiplostimduringtheearlyphaseoftreatmentanitaliansingleinstitutionexperience AT renatoalterini patientswith20x109lplateletsatbaselinemayhaveapromptresponsetoromiplostimduringtheearlyphaseoftreatmentanitaliansingleinstitutionexperience AT rajmondafjerza patientswith20x109lplateletsatbaselinemayhaveapromptresponsetoromiplostimduringtheearlyphaseoftreatmentanitaliansingleinstitutionexperience AT albertobosi patientswith20x109lplateletsatbaselinemayhaveapromptresponsetoromiplostimduringtheearlyphaseoftreatmentanitaliansingleinstitutionexperience |